US 12,139,712 B2
Direct and selective inhibition of MDM4 for treatment of cancer
Jean-Christophe Marine, Linden (BE); Ernesto Guccione, Proteos (SG); and Marco Bezzi, Proteos (SG)
Assigned to VIB VZW, Ghent (BE); KATHOLIEKE UNIVERSITEIT LEUVEN, Leuven (BE); and Agency for Science, Technology and Research, Singapore (SG)
Filed by VIB VZW, Ghent (BE); Katholieke Universiteit Leuven, K.U.Leuven R&D, Leuven (BE); and Agency for Science, Technology and Research (A*Star)
Filed on Aug. 21, 2020, as Appl. No. 16/999,506.
Application 16/999,506 is a division of application No. 15/526,716, granted, now 10,767,182, previously published as PCT/EP2015/076705, filed on Nov. 16, 2015.
Claims priority of application No. 14193193 (EP), filed on Nov. 14, 2014.
Prior Publication US 2020/0392506 A1, Dec. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/506 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01)
CPC C12N 15/1135 (2013.01) [A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/506 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); C12N 2310/11 (2013.01); C12N 2310/3233 (2013.01); C12N 2320/31 (2013.01); C12N 2320/33 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 5 Claims
 
1. An inhibitor of MDM4 which induces exon skipping of exon 6 of MDM and is an antisense oligonucleotide selected from the group consisting of:
an antisense oligonucleotide which binds to the exon 6-intron 6 boundary of exon 6 of MDM4 and overlaps at least one Ser-Arg Splicing Factor 3 (SRSF3) binding site; and
an antisense oligonucleotide comprising the nucleotide sequence of SEQ ID NO: 54;
wherein the antisense oligonucleotide comprises a morpholino or phosphorothioate backbone, or a 2′-O-methyl-modification.